What's Changing in How You Launch

Every Head of Commercial Operations or Country Ops Director at a mid-sized pharma affiliate in Europe has had the same Monday morning. Three launch reviews on this week's calendar. Launch one: an oncology specialty asset, peak projected for Q3, the uptake curve is fourteen percent below the benchmark launches in the therapeutic area and nobody can agree why. Launch two: your senior oncology MSL spent twenty-two hours last week on pre-call preparation, literature monitoring across three competitor assets, and the cross-functional brief the market-access team needed by Friday. Launch three: your twenty-year market-access lead scheduled thirty minutes with you for Thursday. The calendar subject line says career.

You have run commercial operations in this affiliate for fifteen years. The pattern used to be simple. Hire the best field force and medical team the country can field. Run launches on the brand plan. Hold compliance. Protect share of voice. The business was understandable.

Something changed. Your CRM vendor is shipping AI agents in quarterly waves and your reps are using them whether or not training has caught up. Global HQ is putting an AI playbook together and will push it down inside eighteen months. Swedish prescribers and payers are using AI tools themselves, so your field force is no longer the best-prepared person in the room. And you can name the six senior MSLs and market-access leads whose departure inside five years will cost you more than any launch-excellence programme has ever gained you.

This is not a you problem. It is an industry problem and a commercial-operations problem, happening at the same time. Most pharma COOs are treating them as two. The ones who see them as one are going to own the next decade of European pharma commercialisation.

This briefing covers what is happening in your sector, what it means inside your commercial engine, and the three questions your leadership team should answer before the next launch review.

Every regulatory and technology wave your sector absorbed in the last twenty years added new work to the commercial engine. New indications expanded the MSL brief. Digital channels added a marketing layer. Compliance tightened the promotional review. Managed-entry agreements added complexity to market access. Each new layer was absorbed by hiring, training, and more quarterly coordination meetings. The tempo ran on fifteen-year patterns. It worked.

AI is resetting the tempo from three directions at once, and not on a timeline the affiliate controls. Your CRM vendor is shipping pre-call, voice, and next-best-action agents in quarterly waves, and your reps are using them whether or not the training has caught up. Global HQ is standing up an AI playbook and will push it to every affiliate inside twelve to eighteen months. Prescribers and payers are using AI tools to prepare for your MSL visits, which means the preparation asymmetry your field force used to count on is gone. The scope of your commercial work has not shrunk. The cadence the outside world expects has moved.

Your prescribers are already prepped by AI before your MSL walks in. Your payer counterparts are running AI dossier reviews before your market-access team arrives. The affiliate that is still running quarterly coordination meetings is showing up slower than the people it is there to engage.

The competitors in your region are not waiting. A handful of Nordic and continental affiliates have committed serious budget to cross-functional intelligence infrastructure in the last eighteen months. The ones moving first are turning a formulary signal from Wednesday into Monday field execution, instead of carrying it through the next quarterly meeting cycle. They are compressing time-to-peak-uptake by months on assets where the patent clock will not let you claim that revenue back on the back half of the curve. The affiliate that opens that gap first does not need to win on science or price. It wins on how fast the commercial engine moves.

Your sales operations. Your field force is running a call plan built on pre-call prep that now runs on the CRM vendor's AI agents, not on the rep's own weekend reading. Territory design has not been revisited against what an AI-augmented rep can cover. Incentive compensation is still keyed to share-of-voice metrics that no longer separate the top rep from the average. The ops team is working harder to report on a call plan that increasingly reflects last year's commercial reality, not next quarter's.

Your medical operations. The MSL model is capacity-limited by what one person can read, prepare, and remember. Your senior oncology MSL, your senior cardiology MSL, and your senior haematology MSL are each holding a KOL roster they built over fifteen to twenty years. The literature monitoring, congress coverage, and advisory-board preparation work that used to fill their week is now handled by agent infrastructure the vendors are shipping. But the agent briefs do not exist yet inside the affiliate. Your best MSLs are doing work the substrate could do, while the KOL conversations they uniquely can hold get the leftover hours.

Your market-access operations. Joint Clinical Assessments live since January 2025 demand cross-market evidence coordination the affiliate was never structured for. Your market-access lead produces a JCA submission in one market while coordinating with two or three other country affiliates on the same asset. Forty to fifty percent of the senior hours on each submission go into cross-check, formatting, and coordination that could run on infrastructure. The judgment calls, the payer reads, the negotiating instinct, are what those hours should be spent on.

Your compliance operations. Promotional review, medical review, and adverse-event handling are running at a volume the 2019 process was not built for. AI tools can draft adverse-event narratives, cross-check promotional claims against the label, and route documentation for human review. None of that removes compliance judgment from humans. It removes the queue backlog that currently stretches review cycles from days to weeks and slows every launch behind the queue.

Your senior specialists. Your six to fourteen most senior MSLs, market-access leads, and public-affairs veterans are the firm's scarcest resource. They spend twenty to twenty-four hours a week on substrate work: pre-call prep, literature monitoring, dossier formatting, coordination meetings. Twelve to eighteen hours remain for the KOL engagement, payer negotiation, and political reading only they can do. And the retirement or approach-by-competitor conversations are already on your calendar. You know which ones.

Your sector is compressing from below because CRM vendors are shipping AI agents that eat substrate work. Your commercial engine is compressing from above because your senior MSLs and market-access leads spend half their billable week on that same substrate. Same force, two altitudes. But there is a third thing happening that most pharma COOs have not named yet, and it is the one that matters most.

You do not have three problems. You have one. The senior judgment that drives your launches has never been separated from the specialist who carries it. Every uptake drift, every compliance lag, every stuck coordination cycle is a symptom of that single unsolved thing. Let a senior MSL burn out on substrate work, and the KOL roster slows. Let a market-access lead retire with the payer-negotiation instinct still in their head, and the next dossier lands softer. Keep the five commercial functions coordinating through quarterly meetings, and the signal-to-action cycle cannot shorten.

Look at the affiliates pulling ahead. Sales, medical, market access, compliance, and senior-specialist continuity are not five separate programmes. They are one intelligence layer. Every launch makes the layer smarter. The senior MSL who retires contributes to it on the way out. The mid-tier medical analyst learns by using it. The KOL relationship holds because the engagement history lives in it. The same infrastructure that compresses time-to-peak-uptake protects compliance and frees senior judgment.

You have twelve to eighteen months before global HQ's AI playbook arrives and the local window closes. Your question now is whether you build the intelligence layer your affiliate will run on for the next decade, or wait until a playbook designed by someone who has never sat in a Nordic tender gets pushed down from Basel or New Brunswick.

Every pharma COO has had the AI conversation. Most are making the same four decisions. A smaller group is making different ones. The difference is architecture, not tooling.

Three questions every pharma commercial-ops COO is tracking. None of them used to be the same question. They are now.

Four concrete moves any pharma commercial-ops COO can start this quarter. Each touches one part of the commercial engine. Pulled together, they become one layer the affiliate runs on.

The pharma commercial-ops COO has four places to go for help. None of them can do what we do, and each for a specific reason.

The big consulting firms' operations practices will sell an eighteen-month programme delivered by a partner and analysts. They are now Salesforce and Veeva implementation partners. Their incentive is platform deployment, not the coordination redesign your affiliate needs.

The CRM vendor professional-services arms will optimise the individual rep inside their CRM. Their AI agents are capable. They do not touch the handoff between sales, medical, market access, and compliance. The tool runs. The coordination gap holds.

The pharma-specialist boutiques and ex-Big-Pharma-ops advisories will sell a playbook and a deck. Your affiliate has watched that purchase fail once already. The decks go in the drawer. The operating model does not change.

The global HQ AI playbook will arrive in twelve to eighteen months. When it does, the operating model your affiliate runs on for five years is designed by someone who has never sat in a Nordic tender.

The market offers four things you have already said no to. GRAIL is the fifth option.

We start with your commercial leadership team because the change cannot outrun the team's personal understanding of what is possible. Three workshops. Each delivers standalone value. Each earns the right to the next.

The questions where your commercial leadership team cannot agree on an answer are the ones worth an hour on the agenda. Ask these honestly.